Continuous Dopaminergic Stimulation

Mechanism

Related News

Serina Completes Sentinel Dosing in Cohort 1 of Phase Ib Trial for Parkinson’s

Jul 13, 2026

Serina Therapeutics completes sentinel dosing in Cohort 1 of its Phase Ib registrational trial of SER-252 for advanced Parkinson's disease. Safety review recommends continuation; enrollment and dosing ongoing. FDA alignment on 505(b)(2) pathway and registrational status.

Serina Therapeutics Enrolls First Patient in Phase 1b Trial of SER-252 for Parkinson's Disease

Feb 19, 2026

Serina Therapeutics has enrolled the first patient in its Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease in Australia, with dosing expected to begin in the first quarter of 2026.